AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23650882 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-point global coherence scale
Number of subjects: 50
Study 23650882 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-point global coherence scale
Number of subjects: 50
Study 21477035 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening priming agent (Power Swabs) applied prior to whitening treatment.
Number of subjects: 25
Study 21477035 — intervention group
Group type: COMPARATOR
Intervention: No whitening priming agent applied (control group).
Number of subjects: 25
Study 18299766 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR with feedback
Number of subjects: 338
Study 18299766 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR without feedback
Number of subjects: 338
Study 18299766 — intervention group
Group type: COMPARATOR
Intervention: No IVR
Number of subjects: 338
Study 16598082 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 20
Study 16598082 — intervention group
Group type: COMPARATOR
Intervention: Intertransverse fusion (ITF)
Number of subjects: 20
Study 14692438 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron treatment
Number of subjects: 5
Study 14692438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 10758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5, 25, 50, or 100 mg)
Number of subjects: 1030
Study 10758440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 10758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 1030
Study 10758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses combined)
Number of subjects: 1030
Study 10758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses)
Number of subjects: 1030
Study 10758440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 1030
Study 8625628 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam/clonidine (n=54)
Number of subjects: 180
Study 8625628 — intervention group
Group type: EXPERIMENTAL
Intervention: chlormethiazole/haloperidol (n=50)
Number of subjects: 180
Study 8625628 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam/haloperidol (n=55)
Number of subjects: 180
Study 1417173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal glucose infusion
Number of subjects: 32
Study 1417173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucose infusion)
Number of subjects: 32
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 36 X 10(6) U/day for 28 days
Number of subjects: 20
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 50 X 10(6) U/day for 28 days
Number of subjects: 20
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 72 X 10(6) U/day for 28 days
Number of subjects: 20
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 100 X 10(6) U/day for 28 days
Number of subjects: 20
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon combined with prednisolone in 5 patients
Number of subjects: 20
Study 3972231 — intervention group
Group type: COMPARATOR
Intervention: Recombinant leukocyte A interferon alone in 15 patients
Number of subjects: 20
Study 3972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of interferon (36 and 50 X 10(6) U)
Number of subjects: 20
Study 30823414 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (mostly a mixture of Bifidobacteria, Streptococci and Lactobacilli)
Number of subjects: 0
Study 30823414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29489017 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention program involving barrier precautions, active surveillance, and NH staff education
Number of subjects: 418
Study 29489017 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 418
Study 26905278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 4247
Study 26905278 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 4247
Study 24522489 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-percutaneous nephrolithotomy (microperc)
Number of subjects: 20
Study 24522489 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous nephrolithotomy (PNL)
Number of subjects: 20
Study 22364685 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis
Number of subjects: 356
Study 22364685 — intervention group
Group type: COMPARATOR
Intervention: Control (no defibrotide)
Number of subjects: 356
Study 20503801 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory steady-state responses (ASSRs) for complex toneburst stimuli
Number of subjects: 17
Study 20503801 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech feature discrimination (SFD) abilities
Number of subjects: 17
Study 17668530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and topical metronidazole gel 1%
Number of subjects: 0
Study 17668530 — intervention group
Group type: COMPARATOR
Intervention: Topical metronidazole gel 1%
Number of subjects: 0
Study 15383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day + statin
Number of subjects: 769
Study 15383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin
Number of subjects: 769
Study 15383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin (DM subgroup)
Number of subjects: 769
Study 15383192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin (MetS subgroup)
Number of subjects: 769
Study 15383192 — intervention group
Group type: COMPARATOR
Intervention: Placebo + statin
Number of subjects: 769
Study 11385890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 11385890 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0
Study 11385890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 9208336 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 37
Study 9208336 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37
Study 8272249 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtral
Number of subjects: 0
Study 8272249 — intervention group
Group type: EXPERIMENTAL
Intervention: F 60
Number of subjects: 0
Study 8272249 — intervention group
Group type: EXPERIMENTAL
Intervention: All dialysers
Number of subjects: 0
Study 3541997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol
Number of subjects: 65
Study 3541997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31005676 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Participation Improvement Program for parents in neonatal intensive care units (2 weeks duration)
Number of subjects: 66
Study 31005676 — intervention group
Group type: COMPARATOR
Intervention: Routine visits (Control group)
Number of subjects: 66
Study 27825891 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month recall period
Number of subjects: 432
Study 27825891 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month recall period
Number of subjects: 432
Study 27825891 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 3-month and 6-month recall periods
Number of subjects: 432
Study 26894175 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2% hyaluronic acid therapy for 14 days
Number of subjects: 50
Study 26894175 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo application for 14 days
Number of subjects: 50
Study 24424513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 589
Study 24424513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 22536936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 16 weeks
Number of subjects: 66
Study 22536936 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (AC)
Number of subjects: 66
Study 18973518 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytate-containing mouthwash (20 mL, twice daily for 1 min)
Number of subjects: 25
Study 18973518 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 25
Study 18973518 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 25
Study 17577007 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 0
Study 17577007 — intervention group
Group type: COMPARATOR
Intervention: Placebo or other treatment
Number of subjects: 0
Study 17577007 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 16342649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally) from the start of DVd-T treatment (group 1)
Number of subjects: 105
Study 16342649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally) after the start of DVd-T treatment (group 2)
Number of subjects: 105
Study 16342649 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (group 3)
Number of subjects: 105
Study 11991271 — intervention group
Group type: COMPARATOR
Intervention: Sodium tetradecyl sulfate (STS) at 0.25%, 0.5%, or 1.5% depending on vein size
Number of subjects: 129
Study 11991271 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (POL) at 0.5%, 1.0%, or 3% depending on vein size
Number of subjects: 129
Study 10330634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 25
Study 10330634 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 0.5% drops
Number of subjects: 25
Study 8950968 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stents placed percutaneous-transhepatically
Number of subjects: 65
Study 8950968 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic stents
Number of subjects: 65
Study 1900094 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg/day)
Number of subjects: 6
Study 1900094 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (1.6 mg/h x 4 h preceded by 1.6 mg iv bolus)
Number of subjects: 6
Study 7128220 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (low dose: 8.7-13.0 micrograms/ml)
Number of subjects: 14
Study 7128220 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (high dose: 16.0-23.6 micrograms/ml)
Number of subjects: 14
Study 7128220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30409023 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hypertonic saline (HS) inhalation, twice daily for 52 weeks
Number of subjects: 42
Study 30409023 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline (IS) inhalation, twice daily for 52 weeks
Number of subjects: 42
Study 28008093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytics (alteplase)
Number of subjects: 300
Study 25656349 — intervention group
Group type: EXPERIMENTAL
Intervention: LR-based education group (context of Low LR model)
Number of subjects: 454
Study 25656349 — intervention group
Group type: EXPERIMENTAL
Intervention: State Of The Art (SOTA) education group (without emphasis on LR)
Number of subjects: 454
Study 25656349 — intervention group
Group type: COMPARATOR
Intervention: No-intervention Control Group
Number of subjects: 454
Study 23219965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz tACS
Number of subjects: 15
Study 23219965 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz tACS
Number of subjects: 15
Study 23219965 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 21157261 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing Research and Clinical practice through close Collaboration (ARCC) model
Number of subjects: 46
Study 21157261 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 46
Study 19824382 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostamol-UNO 320 mg/day for 36 months
Number of subjects: 0
Study 17145264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally 2-3 hours before MRCP
Number of subjects: 35
Study 15561257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 26
Study 15561257 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine Neoral (CsA)
Number of subjects: 26
Study 11584850 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% hypotonic hyaluronic acid (HHA) eye drops
Number of subjects: 135
Study 11584850 — intervention group
Group type: COMPARATOR
Intervention: 0.3% hydroxypropylmethylcellulose plus 0.1% Dextran 70 (HPMC) eye drops
Number of subjects: 135
Study 8731664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% all-trans retinoic acid (RA) in ethanol
Number of subjects: 0
Study 8731664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% all-trans retinoic acid (RA) in ethanol
Number of subjects: 0
Study 8731664 — intervention group
Group type: COMPARATOR
Intervention: 1% sodium lauryl sulphate (SLS) in water
Number of subjects: 0
Study 8731664 — intervention group
Group type: EXPERIMENTAL
Intervention: RA followed by SLS in tandem design
Number of subjects: 0
Study 8731664 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS followed by RA in tandem design
Number of subjects: 0
Study 1303409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 200
Study 3904434 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg once daily
Number of subjects: 176
Study 3904434 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (long-term phase)
Number of subjects: 176
Study 3904434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 3612496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine HCl 120 mg
Number of subjects: 8
Study 3612496 — intervention group
Group type: EXPERIMENTAL
Intervention: MEGX HCl 120 mg
Number of subjects: 8
Study 3612496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine HCl 120 mg + MEGX HCl 120 mg
Number of subjects: 8
Study 3612496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30172038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension personal control program (HPCP) with home blood pressure monitoring
Number of subjects: 350
Study 30172038 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring alone
Number of subjects: 350
Study 28982109 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342
Study 28982109 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 342
Study 25767371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg) with warfarin (25 mg) on day 5
Number of subjects: 24
Study 25767371 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg) alone
Number of subjects: 24
Study 23067366 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day for 12 months
Number of subjects: 140
Study 23067366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 140
Study 20004274 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (21+7 days)
Number of subjects: 59
Study 20004274 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (84+7 days)
Number of subjects: 59
Study 20004274 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (baseline)
Number of subjects: 59
Study 20666297 — intervention group
Group type: EXPERIMENTAL
Intervention: Care managers linking patients to primary care after psychiatric crisis
Number of subjects: 85
Study 20666297 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative inquiry
Number of subjects: 85
Study 20666297 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care services
Number of subjects: 85
Study 16608035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative adjuvant therapy (hepatectomy plus microwave coagulonecrotic therapy or radiofrequency ablation)
Number of subjects: 30
Study 16608035 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy (transcatheter arterial embolization)
Number of subjects: 30
Study 12667969 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (real needles)
Number of subjects: 22
Study 12667969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo needles)
Number of subjects: 22
Study 10752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Map projection CT colonography (Mercator projection)
Number of subjects: 9
Study 10752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Map projection CT colonography (Stereographic projection)
Number of subjects: 9
Study 10752876 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT colonography (VC)
Number of subjects: 9
Study 10752876 — intervention group
Group type: COMPARATOR
Intervention: Viewing axial slices
Number of subjects: 9
Study 9375593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide treatment for 6 weeks
Number of subjects: 8
Study 9375593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1547677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabeto (computer‐assisted diet education system)
Number of subjects: 105
Study 3890521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose-electrolyte solution with 60 mEq/L sodium and 2% glucose
Number of subjects: 60
Study 3890521 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose-electrolyte solution with 30 mEq/L sodium and 5% glucose
Number of subjects: 60
Study 30221485 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-TNFi
Number of subjects: 2296
Study 30221485 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 2296
Study 30143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 362
Study 30143730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 30143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive children
Number of subjects: 362
Study 27638896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopically guided biopsy
Number of subjects: 82
Study 27638896 — intervention group
Group type: COMPARATOR
Intervention: Blind biopsy
Number of subjects: 82
Study 25238506 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic complex (Atropa belladonna D4, Calcarea phosphoricum D4, Hepar sulphuris D4, Kalium bichromat D4, Kalium muriaticum D4, Mercurius protoiodid D10, and Mercurius biniodid D10)
Number of subjects: 30
Study 25238506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unmedicated vehicle)
Number of subjects: 30
Study 23734933 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy (T12/PR24 group)
Number of subjects: 267
Study 23734933 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐α‐2b and RBV for 48 weeks (PR48 group)
Number of subjects: 267
Study 20484150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.6 mg/kg i.v. bolus)
Number of subjects: 10
Study 20484150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18467727 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 731
Study 18467727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 16648064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate Smoothing On (RS On)
Number of subjects: 569
Study 16648064 — intervention group
Group type: COMPARATOR
Intervention: Rate Smoothing Off (RS Off)
Number of subjects: 569
Study 12859220 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 0
Study 10866897 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-N(2)O
Number of subjects: 60
Study 10866897 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-N(2)O-fentanyl
Number of subjects: 60
Study 9187778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.25%
Number of subjects: 60
Study 9187778 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25%
Number of subjects: 60
Study 1389703 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography
Number of subjects: 131
Study 1389703 — intervention group
Group type: COMPARATOR
Intervention: Precordial echocardiography
Number of subjects: 131
Study 1389703 — intervention group
Group type: COMPARATOR
Intervention: Clinical detection
Number of subjects: 131
Study 3516407 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycinated aspirin swallowed without water (600 mg)
Number of subjects: 16
Study 3516407 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin swallowed with water (600 mg)
Number of subjects: 16
Study 3516407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Glycinated aspirin and Soluble aspirin)
Number of subjects: 16
Study 30768404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (9.5 hours)
Number of subjects: 72
Study 30768404 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (6.5 hours)
Number of subjects: 72
Study 29496036 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 68
Study 29496036 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 68
Study 26613823 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg ethinyl estradiol (EE) with 3mg drospirenone
Number of subjects: 112
Study 26613823 — intervention group
Group type: COMPARATOR
Intervention: 20 μg ethinyl estradiol (EE) with 3mg drospirenone
Number of subjects: 112
Study 26573461 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located vaccination against influenza (SLV-I)
Number of subjects: 18410
Study 26573461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-per-vaccinated child excluding vaccine purchase
Number of subjects: 18410
Study 26573461 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect costs of SLV-I
Number of subjects: 18410